Saturday 17 October 2026
Export HNGE’s income statement to Excel — free account
Hinge Health Inc.
HNGE Healthcare Health Information Services
Hinge Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $587.9 million, up 50.6% from fiscal 2024. In the quarter to June 2026, revenue grew 53.0%, EPS grew 104.2% and free cash flow grew 441.1%, each against the same quarter a year earlier.
99.16
5.80
−5.53%
Follow HNGE
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 5 |
Altman Z-Score |
— | — | (0.64) |
P/S ratio |
0.00 | 0.00 | 4.31 |
Altman Z″-Score (non-manufacturers) |
(0.87) | (0.01) | (7.69) |
P/FCF ratio |
10.90 | 10.90 | 15.33 |
P/Operating CF |
116.93 | 116.93 | 39.68 |
Beneish M-Score |
— | (3.08) | (6.18) |
P/B ratio |
0.00 | 0.00 | 14.19 |
Price to Tangible BV |
0.00 | 0.00 | 22.62 |
EV/Sales |
0.00 | 0.00 | 3.69 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
2.03 | 2.03 | 12.66 |
EV/FCF |
2.07 | 2.07 | 13.13 |
Quick Ratio |
2.55 | 2.04 | 1.19 |
Current Ratio |
2.88 | 2.34 | 1.47 |
Net Debt/EBITDA |
3.67 | (103.89) | 0.74 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.60 | 0.83 |
Operating CF/Net income |
0.59 | (4.11) | (0.40) |
Capex/Depreciation |
(0.30) | (0.10) | (0.12) |
| 0.00% | 2.78% | 331.44% | |
| 0.00% | (1.84%) | (59.81%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(30.47%) | (3.49%) | (233.03%) |
Average Days of Receivables |
58.06 | 39.73 | 41.02 |
Research and Development Expense of Revenue |
37.60% | 25.83% | 62.62% |
Selling, General and Administrative Expense of Revenue |
73.32% | 59.16% | 109.97% |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.09 |
Share Based Compensation of Revenue |
0.56% | 0.19% | 109.38% |
Graham Net Nets |
(0.91) | (0.91) | (0.01) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(24.95%) | (24.95%) | (25.00%) |
Free Cash Flow Yield |
9.18% | 9.18% | 6.52% |
Revenue per Share |
22.49 | 28.80 | 10.77 |
Operating CF per Share |
(4.91) | 3.61 | 3.14 |
Capex per Share |
(0.35) | (0.28) | (0.11) |
Free Cash Flow per Share |
(5.26) | 3.34 | 3.03 |
Cash per Share |
32.52 | 34.41 | 6.67 |
Shareholders Equity per Share |
(32.57) | (32.05) | 3.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(32.57) | (32.05) | 3.27 |
Free Cash Flow |
(68.52) | 45.23 | 165.38 |
Working Capital |
345.73 | 334.15 | 171.50 |
Capital Expenditures |
(4.61) | (3.77) | (6.06) |
Net Current Asset Value |
(516.64) | (524.38) | (32.19) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
1.65 | 4.93 | 4.97 |
Cash ROIC |
10,740.44% | 141.33% | 30.48% |
Accounts Receivable Turnover |
0.00 | 8.77 | 10.83 |
Accounts Payable Turnover |
0.00 | 2.71 | 2.81 |
Inventory Turnover |
0.00 | 7.49 | 9.03 |
Average Days of Payables |
144.61 | 112.33 | 174.91 |
Days of Inventory on Hand |
49.23 | 43.85 | 47.70 |
Average Receivables |
— | 44.53 | 54.28 |
Average Payables |
— | 33.45 | 42.59 |
Average Inventory |
— | 12.08 | 13.25 |
Average Assets |
— | 647.89 | 709.01 |
Average Common Equity |
— | (429.28) | (127.95) |
Columns are period end dates